CJC-1295 (No DAC) / Ipamorelin / GHRP-2 Blend is a research peptide formulation combining three well-studied synthetic peptides commonly examined in growth hormone and endocrine signaling research: CJC-1295 without Drug Affinity Complex (No DAC), Ipamorelin, and Growth Hormone–Releasing Peptide-2 (GHRP-2). CJC-1295 (No DAC) is a modified growth hormone–releasing hormone (GHRH) analog, while Ipamorelin and GHRP-2 are growth hormone secretagogue receptor (GHS-R) agonists with differing receptor activity profiles. Together, this blend is formulated for laboratory research focused on growth hormone pulsatility, receptor signaling pathways, and coordinated endocrine response mechanisms.
Prior to the targeted synthesis and study of these peptides, research into growth hormone modulation relied largely on less selective secretagogues and broader hormonal interventions. In controlled research settings, CJC-1295 (No DAC) has been studied for its ability to stimulate endogenous growth hormone release through GHRH receptor activation while maintaining a shorter duration of activity compared to DAC-bound variants. Ipamorelin has been researched for its selective receptor activity and minimal interaction with other pituitary hormones, while GHRP-2 has been widely studied for its potent receptor binding and influence on growth hormone secretion dynamics. The combination allows researchers to examine complementary mechanisms involved in growth hormone release amplitude, frequency, and signaling coordination.
Currently, the CJC-1295 (No DAC) / Ipamorelin / GHRP-2 Blend is being investigated for its potential applications in metabolic research models, endocrine pathway analysis, recovery-related signaling studies, and age-associated hormone regulation research. Additional investigation continues into its role in downstream anabolic signaling, circadian hormone release patterns, and integrated pituitary response mechanisms. Due to the complementary research interest of these peptides, this blend remains a compelling subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The CJC-1295 (No DAC), Ipamorelin, GHRP-2 Blend is designed for laboratory research focused on growth hormone signaling pathways, endocrine communication systems, and pulsatile hormone response patterns. By combining a growth hormone–releasing hormone analog with two growth hormone secretagogues, researchers can examine how multiple GH-axis signaling inputs interact within controlled experimental environments.
Multi-peptide research blends allow investigators to explore complex signaling relationships across the hypothalamic–pituitary axis. In experimental models, this blend may be used to observe pulse amplitude changes, hormone release patterns, and downstream endocrine marker responses across defined time intervals. Because multi-variable peptide studies introduce additional interpretive complexity, well-structured protocols emphasize strict endpoint definitions, consistent environmental conditions, and detailed experimental documentation.
CJC-1295 (No DAC), Ipamorelin, GHRP-2 Blend – Research Specifications:
| Format | Lyophilized peptide blend (research format) |
| Contents | CJC-1295 (No DAC) + Ipamorelin + GHRP-2 |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific analytical data |
| Source | Peptide synthesis with standardized processing and QC documentation |
| Appearance | Powder (lyophilized) |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
CJC-1295 without DAC is commonly referenced in peptide research as a modified growth hormone–releasing hormone (GHRH) analog used to study pulsatile GH signaling patterns. Because this version lacks the Drug Affinity Complex (DAC) modification present in some long-acting variants, it is often evaluated in experimental designs where researchers want to observe shorter signaling windows and clearer pulse-response behavior.
Ipamorelin and GHRP-2 are both growth hormone secretagogues frequently used in GH-axis research models. These peptides interact with ghrelin receptor–mediated signaling pathways and pituitary response mechanisms, allowing researchers to investigate endocrine signaling responses and downstream metabolic marker movement.
When these three peptides are combined in a research protocol, investigators can evaluate how GHRH pathway stimulation interacts with ghrelin receptor activation across multiple signaling inputs. Experimental models may examine hormone pulse frequency, amplitude variations, and downstream biomarker responses in order to better understand complex endocrine signaling dynamics.
Researchers studying these pathways individually can reference the individual compound pages for CJC-1295 (without DAC), Ipamorelin, and GHRP-2.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across research studies.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
A common research objective for this peptide combination is evaluating pulsatile growth hormone signaling patterns. Researchers may track endocrine marker fluctuations across timed sampling intervals to understand how combined pathway activation influences GH release amplitude and frequency.
Because these peptides interact with multiple components of the GH-axis, they are frequently studied in endocrine signaling experiments exploring pituitary responsiveness and hormone pathway communication dynamics within laboratory models.
Some laboratories design experiments comparing blended peptide protocols to single-variable models. This research approach allows investigators to determine whether signaling responses are additive, synergistic, or primarily attributable to individual pathway activation.
GH-axis studies often intersect with metabolic marker research and cellular signaling experiments. In controlled laboratory environments, investigators may evaluate variables such as endocrine biomarkers, metabolic indicators, and cellular signaling responses influenced by growth hormone activity.
The CJC-1295 (No DAC), Ipamorelin, GHRP-2 Blend should be handled according to standard peptide laboratory protocols emphasizing contamination prevention, proper storage practices, and detailed experimental documentation. Maintaining stable laboratory conditions helps improve reproducibility across research cohorts.
Protocol Design Considerations: Growth hormone signaling research is sensitive to circadian rhythm timing, baseline metabolic phenotype, stress variables, and environmental conditions. Standardized sampling windows and carefully controlled laboratory environments help maintain reliable data interpretation.
Note: The information above is provided solely as a research reference summary. All experimental work must be conducted by qualified researchers in properly equipped laboratory facilities.
Each lot of this peptide blend is supported by a Certificate of Analysis verifying peptide identity and quality parameters. These analytical reports assist laboratories with procurement verification, documentation compliance, and reproducibility tracking across research studies.
Laboratories sourcing peptides for endocrine signaling research typically prioritize traceable documentation, consistent product identity, and reliable quality-control processes. Nordsci Peptides provides research-grade peptide materials supported by analytical documentation and manufacturing standards designed to support reproducible laboratory research.
IMPORTANT: This product is supplied exclusively for laboratory research use. It is not approved for human consumption or clinical application. Researchers are responsible for ensuring compliance with all applicable regulatory and institutional guidelines.
